122 related articles for article (PubMed ID: 38332108)
41. Prognostic and clinicopathological value of PD-L2 in lung cancer: A meta-analysis.
Lin X; Lin K; Lin C; Liu T; Ba M; Tang Y; Wang J; Zhou L; Wang J; Xiao C
Int Immunopharmacol; 2021 Feb; 91():107280. PubMed ID: 33370681
[TBL] [Abstract][Full Text] [Related]
42. Molecular epidemiology study of programmed death ligand 1 and ligand 2 protein expression assessed by immunohistochemistry in extensive-stage small-cell lung cancer.
Steiniche T; Georgsen JB; Meldgaard P; Deitz AC; Ayers M; Pietanza MC; Zu K
Front Oncol; 2023; 13():1225820. PubMed ID: 38269020
[TBL] [Abstract][Full Text] [Related]
43. Construction and Preclinical Evaluation of a
Yao Y; Hou X; Liu S; Liu T; Ren Y; Ma X; Zhang Q; Wang P; Guo Q; Ma X; Yang Z; Zhu H; Li N
Mol Pharm; 2023 Feb; 20(2):1365-1374. PubMed ID: 36579764
[TBL] [Abstract][Full Text] [Related]
44. PD-1, PD-L1 and PD-L2 expression in mouse prostate cancer.
Yang S; Zhang Q; Liu S; Wang AR; You Z
Am J Clin Exp Urol; 2016; 4(1):1-8. PubMed ID: 27069956
[TBL] [Abstract][Full Text] [Related]
45. PD-L2 expression is correlated with the molecular and clinical features of glioma, and acts as an unfavorable prognostic factor.
Wang ZL; Li GZ; Wang QW; Bao ZS; Wang Z; Zhang CB; Jiang T
Oncoimmunology; 2019; 8(2):e1541535. PubMed ID: 30713802
[No Abstract] [Full Text] [Related]
46. Expression of Immunomodulatory Molecules PD-1, PD-L1, and PD-L2, and their Relationship With Clinicopathologic Characteristics in Endometrial Cancer.
Sungu N; Yildirim M; Desdicioglu R; Başaran Aydoğdu Ö; Kiliçarslan A; Tatli Doğan H; Kiliç Yazgan A; Akyol M; Erdoğan F
Int J Gynecol Pathol; 2019 Sep; 38(5):404-413. PubMed ID: 30134343
[TBL] [Abstract][Full Text] [Related]
47. High efficacy of PD-1 inhibitor after initial failure of PD-L1 inhibitor in Relapsed/Refractory classical Hodgkin Lymphoma.
Chen X; Kong H; Luo L; Han S; Lei T; Yu H; Guo N; Li C; Peng S; Dong X; Yang H; Wu M
BMC Cancer; 2022 Jan; 22(1):9. PubMed ID: 34980000
[TBL] [Abstract][Full Text] [Related]
48. Clinicopathological analysis of PD-L2 expression in colorectal cancer.
Guo PD; Sun ZW; Lai HJ; Yang J; Wu PP; Guo YD; Sun J
Onco Targets Ther; 2018; 11():7635-7642. PubMed ID: 30464512
[TBL] [Abstract][Full Text] [Related]
49. Profiles of PD-1, PD-L1, PD-L2 in Gastric Cancer and Their Relation with Mutation, Immune Infiltration, and Survival.
Liu J; Li H; Sun L; Yuan Y; Xing C
Biomed Res Int; 2020; 2020():2496582. PubMed ID: 32596285
[TBL] [Abstract][Full Text] [Related]
50. FasL
Shan ZG; Zhao YL; Zhang JY; Yan ZB; Wang TT; Mao FY; Teng YS; Peng LS; Chen WY; Wang P; Cheng P; Tian WQ; Chen J; Chen W; Zhuang Y
Adv Sci (Weinh); 2022 Feb; 9(5):e2103543. PubMed ID: 34957697
[TBL] [Abstract][Full Text] [Related]
51. Characterization of Viscum album L. Effect on Immune Escape Proteins PD-L1, PD-L2, and MHC-I in the Prostate, Colon, Lung, and Breast Cancer Cells.
Devi S; Gründemann C; Huber R; Kowarschik S
Complement Med Res; 2023; 30(5):386-392. PubMed ID: 36927644
[TBL] [Abstract][Full Text] [Related]
52. PD-L2 Expression as a Potential Predictive Biomarker for the Response to Anti-PD-1 Drugs in Patients with Non-small Cell Lung Cancer.
Takamori S; Takada K; Toyokawa G; Azuma K; Shimokawa M; Jogo T; Yamada Y; Hirai F; Tagawa T; Kawahara A; Akiba J; Okamoto I; Nakanishi Y; Oda Y; Hoshino T; Maehara Y
Anticancer Res; 2018 Oct; 38(10):5897-5901. PubMed ID: 30275216
[TBL] [Abstract][Full Text] [Related]
53. PD-1 and PD-L1 co-expression predicts favorable prognosis in gastric cancer.
Wu Y; Cao D; Qu L; Cao X; Jia Z; Zhao T; Wang Q; Jiang J
Oncotarget; 2017 Sep; 8(38):64066-64082. PubMed ID: 28969052
[TBL] [Abstract][Full Text] [Related]
54. Expression of PD-1 and Its Ligands, PD-L1 and PD-L2, in Smokers and Never Smokers with KRAS-Mutant Lung Cancer.
Calles A; Liao X; Sholl LM; Rodig SJ; Freeman GJ; Butaney M; Lydon C; Dahlberg SE; Hodi FS; Oxnard GR; Jackman DM; Jänne PA
J Thorac Oncol; 2015 Dec; 10(12):1726-35. PubMed ID: 26473645
[TBL] [Abstract][Full Text] [Related]
55. Inhibitory functions of PD-L1 and PD-L2 in the regulation of anti-tumor immunity in murine tumor microenvironment.
Umezu D; Okada N; Sakoda Y; Adachi K; Ojima T; Yamaue H; Eto M; Tamada K
Cancer Immunol Immunother; 2019 Feb; 68(2):201-211. PubMed ID: 30357491
[TBL] [Abstract][Full Text] [Related]
56. PD-L2 modulates asthma severity by directly decreasing dendritic cell IL-12 production.
Lewkowich IP; Lajoie S; Stoffers SL; Suzuki Y; Richgels PK; Dienger K; Sproles AA; Yagita H; Hamid Q; Wills-Karp M
Mucosal Immunol; 2013 Jul; 6(4):728-39. PubMed ID: 23149662
[TBL] [Abstract][Full Text] [Related]
57. Biomimetic Nanoplatform for Dual-Targeted Clearance of Activated and Senescent Cancer-Associated Fibroblasts to Improve Radiation Resistance in Breast Cancer.
Jian C; Wu T; Wang L; Gao C; Fu Z; Zhang Q; Shi C
Small; 2024 Jun; 20(25):e2309279. PubMed ID: 38214439
[TBL] [Abstract][Full Text] [Related]
58. Clinicopathological and Prognostic Analysis of PD-L1 and PD-L2 Expression in Surgically Resected Primary Tongue Squamous Cell Carcinoma.
Furukawa K; Kawasaki G; Yoshida T; Umeda M
Anticancer Res; 2021 Jan; 41(1):101-111. PubMed ID: 33419803
[TBL] [Abstract][Full Text] [Related]
59. PD-L2 expression in colorectal cancer: Independent prognostic effect and targetability by deglycosylation.
Wang H; Yao H; Li C; Liang L; Zhang Y; Shi H; Zhou C; Chen Y; Fang JY; Xu J
Oncoimmunology; 2017; 6(7):e1327494. PubMed ID: 28811964
[TBL] [Abstract][Full Text] [Related]
60. RGMb impacts partial epithelial-mesenchymal transition and BMP2-Induced ID mRNA expression independent of PD-L2 in nonsmall cell lung cancer cells.
Dorset SR; Daugaard TF; Larsen TV; Nielsen AL
Cell Biol Int; 2023 Nov; 47(11):1799-1812. PubMed ID: 37434531
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
